#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	ana	3-1

#Text=It is believed that an ideal vaccine against Leishmania spp .
3-1	15-17	It	abstract	giv	_	_
3-2	18-20	is	_	_	_	_
3-3	21-29	believed	_	_	_	_
3-4	30-34	that	_	_	_	_
3-5	35-37	an	substance[4]	new[4]	_	_
3-6	38-43	ideal	substance[4]	new[4]	_	_
3-7	44-51	vaccine	substance[4]	new[4]	_	_
3-8	52-59	against	substance[4]	new[4]	_	_
3-9	60-70	Leishmania	substance[4]|abstract	new[4]|new	coref	6-27
3-10	71-74	spp	substance[4]	new[4]	_	_
3-11	75-76	.	_	_	_	_

#Text=should have epitopes that will be recognized by APCs and will be able to trigger a T- lymphocyte effector response and maintain a long-lasting immune memory , which would be critical for protection against the parasite .
4-1	77-83	should	_	_	_	_
4-2	84-88	have	_	_	_	_
4-3	89-97	epitopes	object	new	coref	5-7[16_0]
4-4	98-102	that	_	_	_	_
4-5	103-107	will	_	_	_	_
4-6	108-110	be	_	_	_	_
4-7	111-121	recognized	_	_	_	_
4-8	122-124	by	_	_	_	_
4-9	125-129	APCs	abstract	new	_	_
4-10	130-133	and	_	_	_	_
4-11	134-138	will	_	_	_	_
4-12	139-141	be	_	_	_	_
4-13	142-146	able	_	_	_	_
4-14	147-149	to	_	_	_	_
4-15	150-157	trigger	_	_	_	_
4-16	158-159	a	event[10]	new[10]	coref	21-35[168_10]
4-17	160-162	T-	event[10]	new[10]	_	_
4-18	163-173	lymphocyte	person|event[10]	new|new[10]	_	_
4-19	174-182	effector	person|event[10]	new|new[10]	_	_
4-20	183-191	response	event[10]	new[10]	_	_
4-21	192-195	and	_	_	_	_
4-22	196-204	maintain	_	_	_	_
4-23	205-206	a	abstract[12]	new[12]	coref	23-26[182_12]
4-24	207-219	long-lasting	abstract[12]	new[12]	_	_
4-25	220-226	immune	abstract|abstract[12]	new|new[12]	_	_
4-26	227-233	memory	abstract[12]	new[12]	_	_
4-27	234-235	,	_	_	_	_
4-28	236-241	which	_	_	_	_
4-29	242-247	would	_	_	_	_
4-30	248-250	be	_	_	_	_
4-31	251-259	critical	_	_	_	_
4-32	260-263	for	_	_	_	_
4-33	264-274	protection	abstract[13]	new[13]	coref	16-11[0_13]
4-34	275-282	against	abstract[13]	new[13]	_	_
4-35	283-286	the	abstract[13]|person[14]	new[13]|new[14]	_	_
4-36	287-295	parasite	abstract[13]|person[14]	new[13]|new[14]	_	_
4-37	296-297	.	_	_	_	_

#Text=Therefore , the high-throughput search for epitopes with this potential has become one of the greatest current challenges for the rational design of vaccines .
5-1	298-307	Therefore	_	_	_	_
5-2	308-309	,	_	_	_	_
5-3	310-313	the	abstract[15]	new[15]	_	_
5-4	314-329	high-throughput	abstract[15]	new[15]	_	_
5-5	330-336	search	abstract[15]	new[15]	_	_
5-6	337-340	for	abstract[15]	new[15]	_	_
5-7	341-349	epitopes	abstract[15]|object[16]	new[15]|giv[16]	coref	6-23[27_16]
5-8	350-354	with	abstract[15]|object[16]	new[15]|giv[16]	_	_
5-9	355-359	this	abstract[15]|object[16]|abstract[17]	new[15]|giv[16]|new[17]	_	_
5-10	360-369	potential	abstract[15]|object[16]|abstract[17]	new[15]|giv[16]|new[17]	_	_
5-11	370-373	has	_	_	_	_
5-12	374-380	become	_	_	_	_
5-13	381-384	one	object[18]	new[18]	_	_
5-14	385-387	of	object[18]	new[18]	_	_
5-15	388-391	the	object[18]|abstract[19]	new[18]|new[19]	_	_
5-16	392-400	greatest	object[18]|abstract[19]	new[18]|new[19]	_	_
5-17	401-408	current	object[18]|abstract[19]	new[18]|new[19]	_	_
5-18	409-419	challenges	object[18]|abstract[19]	new[18]|new[19]	_	_
5-19	420-423	for	object[18]|abstract[19]	new[18]|new[19]	_	_
5-20	424-427	the	object[18]|abstract[19]|abstract[20]	new[18]|new[19]|new[20]	_	_
5-21	428-436	rational	object[18]|abstract[19]|abstract[20]	new[18]|new[19]|new[20]	_	_
5-22	437-443	design	object[18]|abstract[19]|abstract[20]	new[18]|new[19]|new[20]	_	_
5-23	444-446	of	object[18]|abstract[19]|abstract[20]	new[18]|new[19]|new[20]	_	_
5-24	447-455	vaccines	object[18]|abstract[19]|abstract[20]|substance	new[18]|new[19]|new[20]|new	coref	21-31
5-25	456-457	.	_	_	_	_

#Text=Thus , reverse vaccinology started to be used for this purpose , and one of the strategies used is the search for immunogenic epitopes in whole Leishmania proteomes .
6-1	458-462	Thus	_	_	_	_
6-2	463-464	,	_	_	_	_
6-3	465-472	reverse	abstract[22]	new[22]	_	_
6-4	473-484	vaccinology	abstract[22]	new[22]	_	_
6-5	485-492	started	_	_	_	_
6-6	493-495	to	_	_	_	_
6-7	496-498	be	_	_	_	_
6-8	499-503	used	_	_	_	_
6-9	504-507	for	_	_	_	_
6-10	508-512	this	abstract[23]	new[23]	coref	15-9[106_23]
6-11	513-520	purpose	abstract[23]	new[23]	_	_
6-12	521-522	,	_	_	_	_
6-13	523-526	and	_	_	_	_
6-14	527-530	one	abstract[24]	new[24]	coref	6-20[26_24]
6-15	531-533	of	abstract[24]	new[24]	_	_
6-16	534-537	the	abstract[24]|abstract[25]	new[24]|new[25]	_	_
6-17	538-548	strategies	abstract[24]|abstract[25]	new[24]|new[25]	_	_
6-18	549-553	used	_	_	_	_
6-19	554-556	is	_	_	_	_
6-20	557-560	the	abstract[26]	giv[26]	_	_
6-21	561-567	search	abstract[26]	giv[26]	_	_
6-22	568-571	for	abstract[26]	giv[26]	_	_
6-23	572-583	immunogenic	abstract[26]|object[27]	giv[26]|giv[27]	coref	7-15[35_27]
6-24	584-592	epitopes	abstract[26]|object[27]	giv[26]|giv[27]	_	_
6-25	593-595	in	abstract[26]|object[27]	giv[26]|giv[27]	_	_
6-26	596-601	whole	abstract[26]|object[27]|object[29]	giv[26]|giv[27]|new[29]	coref	7-4[32_29]
6-27	602-612	Leishmania	abstract[26]|object[27]|place|object[29]	giv[26]|giv[27]|giv|new[29]	coref	24-15
6-28	613-622	proteomes	abstract[26]|object[27]|object[29]	giv[26]|giv[27]|new[29]	_	_
6-29	623-624	.	_	_	_	_

#Text=Epitope mapping in proteomes of parasites is much more complex than the mapping of epitopes in proteins already described as immunogenic .
7-1	625-632	Epitope	abstract|abstract[31]	new|new[31]	coref|coref	24-5|24-5
7-2	633-640	mapping	abstract[31]	new[31]	_	_
7-3	641-643	in	abstract[31]	new[31]	_	_
7-4	644-653	proteomes	abstract[31]|object[32]	new[31]|giv[32]	_	_
7-5	654-656	of	abstract[31]|object[32]	new[31]|giv[32]	_	_
7-6	657-666	parasites	abstract[31]|object[32]|animal	new[31]|giv[32]|new	coref	25-11[204_0]
7-7	667-669	is	_	_	_	_
7-8	670-674	much	_	_	_	_
7-9	675-679	more	_	_	_	_
7-10	680-687	complex	_	_	_	_
7-11	688-692	than	_	_	_	_
7-12	693-696	the	abstract[34]	new[34]	_	_
7-13	697-704	mapping	abstract[34]	new[34]	_	_
7-14	705-707	of	abstract[34]	new[34]	_	_
7-15	708-716	epitopes	abstract[34]|object[35]	new[34]|giv[35]	coref	8-32[48_35]
7-16	717-719	in	abstract[34]|object[35]	new[34]|giv[35]	_	_
7-17	720-728	proteins	abstract[34]|object[35]|substance	new[34]|giv[35]|new	_	_
7-18	729-736	already	_	_	_	_
7-19	737-746	described	_	_	_	_
7-20	747-749	as	_	_	_	_
7-21	750-761	immunogenic	_	_	_	_
7-22	762-763	.	_	_	_	_

#Text=In this way , the use of the integrative approach to immunoinformatics proposed by Brito , Guimaraes , Velloso , Correa-Oliveira , Ruiz , Reis and Resende was important to achieve potential epitopes in this study .
8-1	764-766	In	_	_	_	_
8-2	767-771	this	abstract[37]	new[37]	coref	26-2[207_37]
8-3	772-775	way	abstract[37]	new[37]	_	_
8-4	776-777	,	_	_	_	_
8-5	778-781	the	abstract[38]	new[38]	_	_
8-6	782-785	use	abstract[38]	new[38]	_	_
8-7	786-788	of	abstract[38]	new[38]	_	_
8-8	789-792	the	abstract[38]|abstract[39]	new[38]|new[39]	coref	22-5[171_39]
8-9	793-804	integrative	abstract[38]|abstract[39]	new[38]|new[39]	_	_
8-10	805-813	approach	abstract[38]|abstract[39]	new[38]|new[39]	_	_
8-11	814-816	to	abstract[38]|abstract[39]	new[38]|new[39]	_	_
8-12	817-834	immunoinformatics	abstract[38]|abstract[39]|abstract	new[38]|new[39]|new	coref	9-4
8-13	835-843	proposed	_	_	_	_
8-14	844-846	by	_	_	_	_
8-15	847-852	Brito	person	new	_	_
8-16	853-854	,	_	_	_	_
8-17	855-864	Guimaraes	person	new	_	_
8-18	865-866	,	_	_	_	_
8-19	867-874	Velloso	person	new	_	_
8-20	875-876	,	_	_	_	_
8-21	877-892	Correa-Oliveira	person	new	_	_
8-22	893-894	,	_	_	_	_
8-23	895-899	Ruiz	person	new	_	_
8-24	900-901	,	_	_	_	_
8-25	902-906	Reis	person	new	coref	14-3
8-26	907-910	and	_	_	_	_
8-27	911-918	Resende	person	new	_	_
8-28	919-922	was	_	_	_	_
8-29	923-932	important	_	_	_	_
8-30	933-935	to	_	_	_	_
8-31	936-943	achieve	_	_	_	_
8-32	944-953	potential	object[48]	giv[48]	coref	9-14[56_48]
8-33	954-962	epitopes	object[48]	giv[48]	_	_
8-34	963-965	in	object[48]	giv[48]	_	_
8-35	966-970	this	object[48]|object[49]	giv[48]|new[49]	_	_
8-36	971-976	study	object[48]|object[49]	giv[48]|new[49]	_	_
8-37	977-978	.	_	_	_	_

#Text=After employing the immunoinformatics methodologies , we identified MHC class I and class II ligand epitopes comprising mouse and human alleles , due to the absence of predictors comprising dog alleles .
9-1	979-984	After	_	_	_	_
9-2	985-994	employing	_	_	_	_
9-3	995-998	the	abstract[51]	new[51]	_	_
9-4	999-1016	immunoinformatics	abstract|abstract[51]	giv|new[51]	_	_
9-5	1017-1030	methodologies	abstract[51]	new[51]	_	_
9-6	1031-1032	,	_	_	_	_
9-7	1033-1035	we	person	acc	ana	10-8
9-8	1036-1046	identified	_	_	_	_
9-9	1047-1050	MHC	abstract|abstract[54]	new|new[54]	coref|coref	10-19|10-19
9-10	1051-1056	class	abstract[54]	new[54]	_	_
9-11	1057-1058	I	person	acc	_	_
9-12	1059-1062	and	_	_	_	_
9-13	1063-1068	class	_	_	_	_
9-14	1069-1071	II	object[56]	giv[56]	coref	15-14[107_56]
9-15	1072-1078	ligand	object[56]	giv[56]	_	_
9-16	1079-1087	epitopes	object[56]	giv[56]	_	_
9-17	1088-1098	comprising	_	_	_	_
9-18	1099-1104	mouse	animal	new	_	_
9-19	1105-1108	and	_	_	_	_
9-20	1109-1114	human	abstract[58]	new[58]	coref	9-30[62_58]
9-21	1115-1122	alleles	abstract[58]	new[58]	_	_
9-22	1123-1124	,	abstract[58]	new[58]	_	_
9-23	1125-1128	due	abstract[58]	new[58]	_	_
9-24	1129-1131	to	_	_	_	_
9-25	1132-1135	the	abstract[59]	new[59]	_	_
9-26	1136-1143	absence	abstract[59]	new[59]	_	_
9-27	1144-1146	of	abstract[59]	new[59]	_	_
9-28	1147-1157	predictors	abstract[59]|abstract	new[59]|new	_	_
9-29	1158-1168	comprising	_	_	_	_
9-30	1169-1172	dog	animal|abstract[62]	new|giv[62]	coref|coref	10-19[68_62]|10-19[68_62]
9-31	1173-1180	alleles	abstract[62]	giv[62]	_	_
9-32	1181-1182	.	_	_	_	_

#Text=However , based on some studies , we can verify that there are high levels of identity between MHC alleles of dogs and those of humans and mice .
10-1	1183-1190	However	_	_	_	_
10-2	1191-1192	,	_	_	_	_
10-3	1193-1198	based	_	_	_	_
10-4	1199-1201	on	_	_	_	_
10-5	1202-1206	some	abstract[63]	new[63]	coref	13-1[89_63]
10-6	1207-1214	studies	abstract[63]	new[63]	_	_
10-7	1215-1216	,	_	_	_	_
10-8	1217-1219	we	person	giv	ana	12-15
10-9	1220-1223	can	_	_	_	_
10-10	1224-1230	verify	_	_	_	_
10-11	1231-1235	that	_	_	_	_
10-12	1236-1241	there	_	_	_	_
10-13	1242-1245	are	_	_	_	_
10-14	1246-1250	high	abstract[65]	new[65]	_	_
10-15	1251-1257	levels	abstract[65]	new[65]	_	_
10-16	1258-1260	of	abstract[65]	new[65]	_	_
10-17	1261-1269	identity	abstract[65]|abstract[66]	new[65]|new[66]	coref	11-14[76_66]
10-18	1270-1277	between	abstract[65]|abstract[66]	new[65]|new[66]	_	_
10-19	1278-1281	MHC	abstract[65]|abstract[66]|abstract|abstract[68]	new[65]|new[66]|giv|giv[68]	coref|coref	11-8|11-8
10-20	1282-1289	alleles	abstract[65]|abstract[66]|abstract[68]	new[65]|new[66]|giv[68]	_	_
10-21	1290-1292	of	abstract[65]|abstract[66]|abstract[68]	new[65]|new[66]|giv[68]	_	_
10-22	1293-1297	dogs	abstract[65]|abstract[66]|abstract[68]|animal	new[65]|new[66]|giv[68]|new	coref	11-12
10-23	1298-1301	and	abstract[65]|abstract[66]|abstract[68]	new[65]|new[66]|giv[68]	_	_
10-24	1302-1307	those	abstract[65]|abstract[66]|abstract[68]	new[65]|new[66]|giv[68]	_	_
10-25	1308-1310	of	abstract[65]|abstract[66]|abstract[68]	new[65]|new[66]|giv[68]	_	_
10-26	1311-1317	humans	abstract[65]|abstract[66]|abstract[68]|person	new[65]|new[66]|giv[68]|new	coref	11-19
10-27	1318-1321	and	abstract[65]|abstract[66]|abstract[68]	new[65]|new[66]|giv[68]	_	_
10-28	1322-1326	mice	abstract[65]|abstract[66]|abstract[68]|animal	new[65]|new[66]|giv[68]|new	coref	11-21
10-29	1327-1328	.	_	_	_	_

#Text=For example , some loci of the MHC region II of dogs have an identity with those of humans and mice around 85 % and 79 % , respectively .
11-1	1329-1332	For	_	_	_	_
11-2	1333-1340	example	_	_	_	_
11-3	1341-1342	,	_	_	_	_
11-4	1343-1347	some	abstract[72]	new[72]	_	_
11-5	1348-1352	loci	abstract[72]	new[72]	_	_
11-6	1353-1355	of	abstract[72]	new[72]	_	_
11-7	1356-1359	the	abstract[72]|abstract[74]	new[72]|new[74]	_	_
11-8	1360-1363	MHC	abstract[72]|place|abstract[74]	new[72]|giv|new[74]	_	_
11-9	1364-1370	region	abstract[72]|abstract[74]	new[72]|new[74]	_	_
11-10	1371-1373	II	abstract[72]|abstract[74]	new[72]|new[74]	_	_
11-11	1374-1376	of	abstract[72]|abstract[74]	new[72]|new[74]	_	_
11-12	1377-1381	dogs	abstract[72]|abstract[74]|animal	new[72]|new[74]|giv	coref	12-17[86_0]
11-13	1382-1386	have	_	_	_	_
11-14	1387-1389	an	abstract[76]	giv[76]	_	_
11-15	1390-1398	identity	abstract[76]	giv[76]	_	_
11-16	1399-1403	with	abstract[76]	giv[76]	_	_
11-17	1404-1409	those	abstract[76]	giv[76]	_	_
11-18	1410-1412	of	abstract[76]	giv[76]	_	_
11-19	1413-1419	humans	abstract[76]|person	giv[76]|giv	coref	13-8[91_0]
11-20	1420-1423	and	abstract[76]	giv[76]	_	_
11-21	1424-1428	mice	abstract[76]|animal	giv[76]|giv	_	_
11-22	1429-1435	around	abstract[76]|quantity[79]	giv[76]|new[79]	_	_
11-23	1436-1438	85	abstract[76]|quantity[79]	giv[76]|new[79]	_	_
11-24	1439-1440	%	abstract[76]|quantity[79]	giv[76]|new[79]	_	_
11-25	1441-1444	and	abstract[76]	giv[76]	_	_
11-26	1445-1447	79	abstract[76]|quantity[80]	giv[76]|new[80]	_	_
11-27	1448-1449	%	abstract[76]|quantity[80]	giv[76]|new[80]	_	_
11-28	1450-1451	,	_	_	_	_
11-29	1452-1464	respectively	_	_	_	_
11-30	1465-1466	.	_	_	_	_

#Text=Regarding the in vivo screening of the immunoinformatics-selected peptides in the canine model , we selected asymptomatic dogs naturally infected by L. infantum ( natural reservoir ) .
12-1	1467-1476	Regarding	_	_	_	_
12-2	1477-1480	the	abstract[81]	new[81]	coref	15-4[105_81]
12-3	1481-1483	in	abstract[81]	new[81]	_	_
12-4	1484-1488	vivo	abstract[81]	new[81]	_	_
12-5	1489-1498	screening	abstract[81]	new[81]	_	_
12-6	1499-1501	of	abstract[81]	new[81]	_	_
12-7	1502-1505	the	abstract[81]|substance[82]	new[81]|new[82]	coref	15-21[0_82]
12-8	1506-1532	immunoinformatics-selected	abstract[81]|substance[82]	new[81]|new[82]	_	_
12-9	1533-1541	peptides	abstract[81]|substance[82]	new[81]|new[82]	_	_
12-10	1542-1544	in	abstract[81]|substance[82]	new[81]|new[82]	_	_
12-11	1545-1548	the	abstract[81]|substance[82]|abstract[84]	new[81]|new[82]|new[84]	coref	20-12[151_84]
12-12	1549-1555	canine	abstract[81]|substance[82]|animal|abstract[84]	new[81]|new[82]|new|new[84]	_	_
12-13	1556-1561	model	abstract[81]|substance[82]|abstract[84]	new[81]|new[82]|new[84]	_	_
12-14	1562-1563	,	_	_	_	_
12-15	1564-1566	we	person	giv	ana	15-2
12-16	1567-1575	selected	_	_	_	_
12-17	1576-1588	asymptomatic	animal[86]	giv[86]	coref	13-6[90_86]
12-18	1589-1593	dogs	animal[86]	giv[86]	_	_
12-19	1594-1603	naturally	_	_	_	_
12-20	1604-1612	infected	_	_	_	_
12-21	1613-1615	by	_	_	_	_
12-22	1616-1618	L.	person	new	_	_
12-23	1619-1627	infantum	_	_	_	_
12-24	1628-1629	(	_	_	_	_
12-25	1630-1637	natural	place[88]	new[88]	_	_
12-26	1638-1647	reservoir	place[88]	new[88]	_	_
12-27	1648-1649	)	_	_	_	_
12-28	1650-1651	.	_	_	_	_

#Text=Several studies have shown that dogs and humans with asymptomatic clinical forms have better reactivity with intra-dermal reaction than symptomatic individuals .
13-1	1652-1659	Several	abstract[89]	giv[89]	coref	20-6[148_89]
13-2	1660-1667	studies	abstract[89]	giv[89]	_	_
13-3	1668-1672	have	_	_	_	_
13-4	1673-1678	shown	_	_	_	_
13-5	1679-1683	that	_	_	_	_
13-6	1684-1688	dogs	animal[90]	giv[90]	coref	14-11[97_90]
13-7	1689-1692	and	animal[90]	giv[90]	_	_
13-8	1693-1699	humans	animal[90]|person[91]	giv[90]|giv[91]	_	_
13-9	1700-1704	with	animal[90]|person[91]	giv[90]|giv[91]	_	_
13-10	1705-1717	asymptomatic	animal[90]|person[91]|abstract[92]	giv[90]|giv[91]|new[92]	_	_
13-11	1718-1726	clinical	animal[90]|person[91]|abstract[92]	giv[90]|giv[91]|new[92]	_	_
13-12	1727-1732	forms	animal[90]|person[91]|abstract[92]	giv[90]|giv[91]|new[92]	_	_
13-13	1733-1737	have	_	_	_	_
13-14	1738-1744	better	abstract[93]	new[93]	_	_
13-15	1745-1755	reactivity	abstract[93]	new[93]	_	_
13-16	1756-1760	with	abstract[93]	new[93]	_	_
13-17	1761-1773	intra-dermal	abstract[93]|event[94]	new[93]|new[94]	_	_
13-18	1774-1782	reaction	abstract[93]|event[94]	new[93]|new[94]	_	_
13-19	1783-1787	than	abstract[93]|event[94]	new[93]|new[94]	_	_
13-20	1788-1799	symptomatic	abstract[93]|event[94]|person[95]	new[93]|new[94]|new[95]	_	_
13-21	1800-1811	individuals	abstract[93]|event[94]|person[95]	new[93]|new[94]|new[95]	_	_
13-22	1812-1813	.	_	_	_	_

#Text=Similarly , Reis , et al. have already shown that asymptomatic dogs have a profile of circulating lymphocytes in the peripheral blood capable of conferring a degree of resistance to the disease .
14-1	1814-1823	Similarly	_	_	_	_
14-2	1824-1825	,	_	_	_	_
14-3	1826-1830	Reis	person	giv	_	_
14-4	1831-1832	,	_	_	_	_
14-5	1833-1835	et	_	_	_	_
14-6	1836-1839	al.	_	_	_	_
14-7	1840-1844	have	_	_	_	_
14-8	1845-1852	already	_	_	_	_
14-9	1853-1858	shown	_	_	_	_
14-10	1859-1863	that	_	_	_	_
14-11	1864-1876	asymptomatic	animal[97]	giv[97]	_	_
14-12	1877-1881	dogs	animal[97]	giv[97]	_	_
14-13	1882-1886	have	_	_	_	_
14-14	1887-1888	a	object[98]	new[98]	_	_
14-15	1889-1896	profile	object[98]	new[98]	_	_
14-16	1897-1899	of	_	_	_	_
14-17	1900-1911	circulating	_	_	_	_
14-18	1912-1923	lymphocytes	substance[99]	new[99]	_	_
14-19	1924-1926	in	substance[99]	new[99]	_	_
14-20	1927-1930	the	substance[99]|object[100]	new[99]|new[100]	_	_
14-21	1931-1941	peripheral	substance[99]|object[100]	new[99]|new[100]	_	_
14-22	1942-1947	blood	substance[99]|object[100]	new[99]|new[100]	_	_
14-23	1948-1955	capable	_	_	_	_
14-24	1956-1958	of	_	_	_	_
14-25	1959-1969	conferring	_	_	_	_
14-26	1970-1971	a	abstract[101]	new[101]	_	_
14-27	1972-1978	degree	abstract[101]	new[101]	_	_
14-28	1979-1981	of	abstract[101]	new[101]	_	_
14-29	1982-1992	resistance	abstract[101]|abstract[102]	new[101]|new[102]	coref	18-10[0_102]
14-30	1993-1995	to	abstract[101]|abstract[102]	new[101]|new[102]	_	_
14-31	1996-1999	the	abstract[101]|abstract[102]|abstract[103]	new[101]|new[102]|new[103]	_	_
14-32	2000-2007	disease	abstract[101]|abstract[102]|abstract[103]	new[101]|new[102]|new[103]	_	_
14-33	2008-2009	.	_	_	_	_

#Text=When we performed the in vitro screening , the purpose was to identify potential epitopes in a huge number of peptides .
15-1	2010-2014	When	_	_	_	_
15-2	2015-2017	we	person	giv	ana	16-4
15-3	2018-2027	performed	_	_	_	_
15-4	2028-2031	the	abstract[105]	giv[105]	coref	21-2[159_105]
15-5	2032-2034	in	abstract[105]	giv[105]	_	_
15-6	2035-2040	vitro	abstract[105]	giv[105]	_	_
15-7	2041-2050	screening	abstract[105]	giv[105]	_	_
15-8	2051-2052	,	_	_	_	_
15-9	2053-2056	the	abstract[106]	giv[106]	_	_
15-10	2057-2064	purpose	abstract[106]	giv[106]	_	_
15-11	2065-2068	was	_	_	_	_
15-12	2069-2071	to	_	_	_	_
15-13	2072-2080	identify	_	_	_	_
15-14	2081-2090	potential	object[107]	giv[107]	_	_
15-15	2091-2099	epitopes	object[107]	giv[107]	_	_
15-16	2100-2102	in	_	_	_	_
15-17	2103-2104	a	object[108]	new[108]	_	_
15-18	2105-2109	huge	object[108]	new[108]	_	_
15-19	2110-2116	number	object[108]	new[108]	_	_
15-20	2117-2119	of	object[108]	new[108]	_	_
15-21	2120-2128	peptides	object[108]|substance	new[108]|giv	coref	19-5[142_0]
15-22	2129-2130	.	_	_	_	_

#Text=For this , we focused on the main biomarkers of protection , namely : lymphocyte proliferation after stimulation with L. infantum and IFN-γ production by subpopulations of T-lymphocytes ( CD4+ and CD8+ ) .
16-1	2131-2134	For	_	_	_	_
16-2	2135-2139	this	_	_	_	_
16-3	2140-2141	,	_	_	_	_
16-4	2142-2144	we	person	giv	ana	18-4
16-5	2145-2152	focused	_	_	_	_
16-6	2153-2155	on	_	_	_	_
16-7	2156-2159	the	abstract[111]	new[111]	appos	16-13[114_111]
16-8	2160-2164	main	abstract[111]	new[111]	_	_
16-9	2165-2175	biomarkers	abstract[111]	new[111]	_	_
16-10	2176-2178	of	abstract[111]	new[111]	_	_
16-11	2179-2189	protection	abstract[111]|abstract	new[111]|giv	coref	17-7
16-12	2190-2191	,	_	_	_	_
16-13	2192-2198	namely	abstract[114]	giv[114]	coref	18-1[132_114]
16-14	2199-2200	:	abstract[114]	giv[114]	_	_
16-15	2201-2211	lymphocyte	abstract|abstract[114]	new|giv[114]	_	_
16-16	2212-2225	proliferation	abstract[114]	giv[114]	_	_
16-17	2226-2231	after	abstract[114]	giv[114]	_	_
16-18	2232-2243	stimulation	abstract[114]|event[115]	giv[114]|new[115]	_	_
16-19	2244-2248	with	abstract[114]|event[115]	giv[114]|new[115]	_	_
16-20	2249-2251	L.	abstract[114]|event[115]	giv[114]|new[115]	_	_
16-21	2252-2260	infantum	abstract[114]|event[115]	giv[114]|new[115]	_	_
16-22	2261-2264	and	abstract[114]|event[115]	giv[114]|new[115]	_	_
16-23	2265-2270	IFN-γ	abstract[114]|event[115]|object|abstract[117]	giv[114]|new[115]|new|new[117]	coref|coref|coref|coref	17-17[124_117]|19-16[145_0]|17-17[124_117]|19-16[145_0]
16-24	2271-2281	production	abstract[114]|event[115]|abstract[117]	giv[114]|new[115]|new[117]	_	_
16-25	2282-2284	by	_	_	_	_
16-26	2285-2299	subpopulations	object[118]	new[118]	_	_
16-27	2300-2302	of	object[118]	new[118]	_	_
16-28	2303-2316	T-lymphocytes	object[118]|abstract	new[118]|new	appos	16-30[120_0]
16-29	2317-2318	(	_	_	_	_
16-30	2319-2323	CD4+	abstract[120]	giv[120]	coref	17-27[129_120]
16-31	2324-2327	and	abstract[120]	giv[120]	_	_
16-32	2328-2332	CD8+	abstract[120]	giv[120]	_	_
16-33	2333-2334	)	_	_	_	_
16-34	2335-2336	.	_	_	_	_

#Text=Currently , some markers related to protection have been studied , such as proinflammatory cytokines , production of immunoglobulins of IgG1 and IgG2 subtypes , and responsive CD4+ and CD8+ T-cells .
17-1	2337-2346	Currently	_	_	_	_
17-2	2347-2348	,	_	_	_	_
17-3	2349-2353	some	abstract[121]	new[121]	_	_
17-4	2354-2361	markers	abstract[121]	new[121]	_	_
17-5	2362-2369	related	_	_	_	_
17-6	2370-2372	to	_	_	_	_
17-7	2373-2383	protection	abstract	giv	coref	25-17[205_0]
17-8	2384-2388	have	_	_	_	_
17-9	2389-2393	been	_	_	_	_
17-10	2394-2401	studied	_	_	_	_
17-11	2402-2403	,	_	_	_	_
17-12	2404-2408	such	_	_	_	_
17-13	2409-2411	as	_	_	_	_
17-14	2412-2427	proinflammatory	abstract[123]	new[123]	coref	23-34[184_123]
17-15	2428-2437	cytokines	abstract[123]	new[123]	_	_
17-16	2438-2439	,	_	_	_	_
17-17	2440-2450	production	abstract[124]	giv[124]	_	_
17-18	2451-2453	of	abstract[124]	giv[124]	_	_
17-19	2454-2469	immunoglobulins	abstract[124]|object[125]	giv[124]|new[125]	_	_
17-20	2470-2472	of	abstract[124]|object[125]	giv[124]|new[125]	_	_
17-21	2473-2477	IgG1	abstract[124]|object[125]|object	giv[124]|new[125]|new	_	_
17-22	2478-2481	and	abstract[124]|object[125]	giv[124]|new[125]	_	_
17-23	2482-2486	IgG2	abstract[124]|object[125]|abstract|abstract[128]	giv[124]|new[125]|new|new[128]	_	_
17-24	2487-2495	subtypes	abstract[124]|object[125]|abstract[128]	giv[124]|new[125]|new[128]	_	_
17-25	2496-2497	,	_	_	_	_
17-26	2498-2501	and	_	_	_	_
17-27	2502-2512	responsive	abstract[129]	giv[129]	coref	17-30[0_129]
17-28	2513-2517	CD4+	abstract[129]	giv[129]	_	_
17-29	2518-2521	and	_	_	_	_
17-30	2522-2526	CD8+	abstract|abstract[131]	giv|new[131]	coref|coref	19-18[146_131]|19-18[146_131]
17-31	2527-2534	T-cells	abstract[131]	new[131]	_	_
17-32	2535-2536	.	_	_	_	_

#Text=The biomarkers that we chose are essential to determine resistance or susceptibility to visceral leishmaniasis and they are widely demonstrated in the literature .
18-1	2537-2540	The	abstract[132]	giv[132]	_	_
18-2	2541-2551	biomarkers	abstract[132]	giv[132]	_	_
18-3	2552-2556	that	_	_	_	_
18-4	2557-2559	we	person	giv	ana	19-1
18-5	2560-2565	chose	_	_	_	_
18-6	2566-2569	are	_	_	_	_
18-7	2570-2579	essential	_	_	_	_
18-8	2580-2582	to	_	_	_	_
18-9	2583-2592	determine	_	_	_	_
18-10	2593-2603	resistance	abstract|abstract[135]	giv|new[135]	ana|ana	18-17[0_135]|18-17[0_135]
18-11	2604-2606	or	abstract[135]	new[135]	_	_
18-12	2607-2621	susceptibility	abstract[135]|abstract[136]	new[135]|new[136]	_	_
18-13	2622-2624	to	abstract[135]|abstract[136]	new[135]|new[136]	_	_
18-14	2625-2633	visceral	abstract[135]|abstract[136]|abstract[137]	new[135]|new[136]|new[137]	coref	20-19[0_137]
18-15	2634-2647	leishmaniasis	abstract[135]|abstract[136]|abstract[137]	new[135]|new[136]|new[137]	_	_
18-16	2648-2651	and	_	_	_	_
18-17	2652-2656	they	abstract	giv	_	_
18-18	2657-2660	are	_	_	_	_
18-19	2661-2667	widely	_	_	_	_
18-20	2668-2680	demonstrated	_	_	_	_
18-21	2681-2683	in	_	_	_	_
18-22	2684-2687	the	abstract[139]	new[139]	_	_
18-23	2688-2698	literature	abstract[139]	new[139]	_	_
18-24	2699-2700	.	_	_	_	_

#Text=Our data support that some peptides were able to induce lymphoproliferation and the production of IFN-γ by T-cells in vitro .
19-1	2701-2704	Our	person|abstract[141]	giv|new[141]	ana|ana	22-1|22-1
19-2	2705-2709	data	abstract[141]	new[141]	_	_
19-3	2710-2717	support	_	_	_	_
19-4	2718-2722	that	_	_	_	_
19-5	2723-2727	some	substance[142]	giv[142]	coref	20-31[158_142]
19-6	2728-2736	peptides	substance[142]	giv[142]	_	_
19-7	2737-2741	were	_	_	_	_
19-8	2742-2746	able	_	_	_	_
19-9	2747-2749	to	_	_	_	_
19-10	2750-2756	induce	_	_	_	_
19-11	2757-2776	lymphoproliferation	abstract	new	_	_
19-12	2777-2780	and	_	_	_	_
19-13	2781-2784	the	event[144]	new[144]	_	_
19-14	2785-2795	production	event[144]	new[144]	_	_
19-15	2796-2798	of	event[144]	new[144]	_	_
19-16	2799-2804	IFN-γ	event[144]|object[145]	new[144]|giv[145]	coref	20-26[0_145]
19-17	2805-2807	by	event[144]|object[145]	new[144]|giv[145]	_	_
19-18	2808-2815	T-cells	event[144]|object[145]|abstract[146]	new[144]|giv[145]|giv[146]	_	_
19-19	2816-2818	in	event[144]|object[145]|abstract[146]	new[144]|giv[145]|giv[146]	_	_
19-20	2819-2824	vitro	event[144]|object[145]|abstract[146]	new[144]|giv[145]|giv[146]	_	_
19-21	2825-2826	.	_	_	_	_

#Text=In this regard , in many studies reporting the use of murine model and PBMC from patients with leishmaniasis , the main biomarker analyzed was IFN-γ produced after stimuli with different peptides .
20-1	2827-2829	In	_	_	_	_
20-2	2830-2834	this	abstract[147]	new[147]	_	_
20-3	2835-2841	regard	abstract[147]	new[147]	_	_
20-4	2842-2843	,	_	_	_	_
20-5	2844-2846	in	_	_	_	_
20-6	2847-2851	many	abstract[148]	giv[148]	_	_
20-7	2852-2859	studies	abstract[148]	giv[148]	_	_
20-8	2860-2869	reporting	_	_	_	_
20-9	2870-2873	the	abstract[149]	new[149]	_	_
20-10	2874-2877	use	abstract[149]	new[149]	_	_
20-11	2878-2880	of	abstract[149]	new[149]	_	_
20-12	2881-2887	murine	abstract[149]|animal|abstract[151]	new[149]|new|giv[151]	coref|coref	22-25[177_151]|22-25[177_151]
20-13	2888-2893	model	abstract[149]|abstract[151]	new[149]|giv[151]	_	_
20-14	2894-2897	and	abstract[149]	new[149]	_	_
20-15	2898-2902	PBMC	abstract[149]|abstract[152]	new[149]|new[152]	_	_
20-16	2903-2907	from	abstract[149]|abstract[152]	new[149]|new[152]	_	_
20-17	2908-2916	patients	abstract[149]|abstract[152]|person[153]	new[149]|new[152]|new[153]	_	_
20-18	2917-2921	with	abstract[149]|abstract[152]|person[153]	new[149]|new[152]|new[153]	_	_
20-19	2922-2935	leishmaniasis	abstract[149]|abstract[152]|person[153]|abstract	new[149]|new[152]|new[153]|giv	_	_
20-20	2936-2937	,	_	_	_	_
20-21	2938-2941	the	abstract[155]	new[155]	_	_
20-22	2942-2946	main	abstract[155]	new[155]	_	_
20-23	2947-2956	biomarker	abstract[155]	new[155]	_	_
20-24	2957-2965	analyzed	_	_	_	_
20-25	2966-2969	was	_	_	_	_
20-26	2970-2975	IFN-γ	abstract	giv	coref	23-39
20-27	2976-2984	produced	_	_	_	_
20-28	2985-2990	after	_	_	_	_
20-29	2991-2998	stimuli	abstract[157]	new[157]	_	_
20-30	2999-3003	with	abstract[157]	new[157]	_	_
20-31	3004-3013	different	abstract[157]|substance[158]	new[157]|giv[158]	coref	22-13[0_158]
20-32	3014-3022	peptides	abstract[157]|substance[158]	new[157]|giv[158]	_	_
20-33	3023-3024	.	_	_	_	_

#Text=After the in vitro screening , the reverse antigen screening ( RAS ) was used , a robust methodology that allows the selection of promising targets for the development of vaccines intended to trigger a strong cellular response .
21-1	3025-3030	After	_	_	_	_
21-2	3031-3034	the	abstract[159]	giv[159]	coref	21-7[161_159]
21-3	3035-3037	in	abstract[159]	giv[159]	_	_
21-4	3038-3043	vitro	abstract[159]	giv[159]	_	_
21-5	3044-3053	screening	abstract[159]	giv[159]	_	_
21-6	3054-3055	,	_	_	_	_
21-7	3056-3059	the	abstract[161]	giv[161]	appos	21-12[0_161]
21-8	3060-3067	reverse	abstract[161]	giv[161]	_	_
21-9	3068-3075	antigen	substance|abstract[161]	new|giv[161]	coref	23-4[179_0]
21-10	3076-3085	screening	abstract[161]	giv[161]	_	_
21-11	3086-3087	(	_	_	_	_
21-12	3088-3091	RAS	abstract	giv	_	_
21-13	3092-3093	)	_	_	_	_
21-14	3094-3097	was	_	_	_	_
21-15	3098-3102	used	_	_	_	_
21-16	3103-3104	,	_	_	_	_
21-17	3105-3106	a	abstract[163]	new[163]	_	_
21-18	3107-3113	robust	abstract[163]	new[163]	_	_
21-19	3114-3125	methodology	abstract[163]	new[163]	_	_
21-20	3126-3130	that	_	_	_	_
21-21	3131-3137	allows	_	_	_	_
21-22	3138-3141	the	abstract[164]	new[164]	_	_
21-23	3142-3151	selection	abstract[164]	new[164]	_	_
21-24	3152-3154	of	abstract[164]	new[164]	_	_
21-25	3155-3164	promising	abstract[164]|abstract[165]	new[164]|new[165]	_	_
21-26	3165-3172	targets	abstract[164]|abstract[165]	new[164]|new[165]	_	_
21-27	3173-3176	for	abstract[164]|abstract[165]	new[164]|new[165]	_	_
21-28	3177-3180	the	abstract[164]|abstract[165]|event[166]	new[164]|new[165]|new[166]	_	_
21-29	3181-3192	development	abstract[164]|abstract[165]|event[166]	new[164]|new[165]|new[166]	_	_
21-30	3193-3195	of	abstract[164]|abstract[165]|event[166]	new[164]|new[165]|new[166]	_	_
21-31	3196-3204	vaccines	abstract[164]|abstract[165]|event[166]|substance	new[164]|new[165]|new[166]|giv	coref	26-23
21-32	3205-3213	intended	_	_	_	_
21-33	3214-3216	to	_	_	_	_
21-34	3217-3224	trigger	_	_	_	_
21-35	3225-3226	a	event[168]	giv[168]	coref	22-21[176_168]
21-36	3227-3233	strong	event[168]	giv[168]	_	_
21-37	3234-3242	cellular	event[168]	giv[168]	_	_
21-38	3243-3251	response	event[168]	giv[168]	_	_
21-39	3252-3253	.	_	_	_	_

#Text=Our findings demonstrate that an immunoinformatic approach increases the chance of finding peptides molecules ( epitopes ) which can trigger a cellular response in a naturally and asymptomatic infected model .
22-1	3254-3257	Our	person|abstract[170]	giv|new[170]	ana|ana	24-2|24-2
22-2	3258-3266	findings	abstract[170]	new[170]	_	_
22-3	3267-3278	demonstrate	_	_	_	_
22-4	3279-3283	that	_	_	_	_
22-5	3284-3286	an	abstract[171]	giv[171]	_	_
22-6	3287-3303	immunoinformatic	abstract[171]	giv[171]	_	_
22-7	3304-3312	approach	abstract[171]	giv[171]	_	_
22-8	3313-3322	increases	_	_	_	_
22-9	3323-3326	the	abstract[172]	new[172]	_	_
22-10	3327-3333	chance	abstract[172]	new[172]	_	_
22-11	3334-3336	of	_	_	_	_
22-12	3337-3344	finding	_	_	_	_
22-13	3345-3353	peptides	substance|object[174]	giv|new[174]	appos|coref|appos|coref	22-16[0_174]|24-8[190_0]|22-16[0_174]|24-8[190_0]
22-14	3354-3363	molecules	object[174]	new[174]	_	_
22-15	3364-3365	(	_	_	_	_
22-16	3366-3374	epitopes	object	giv	coref	26-18[213_0]
22-17	3375-3376	)	_	_	_	_
22-18	3377-3382	which	_	_	_	_
22-19	3383-3386	can	_	_	_	_
22-20	3387-3394	trigger	_	_	_	_
22-21	3395-3396	a	event[176]	giv[176]	coref	23-7[180_176]
22-22	3397-3405	cellular	event[176]	giv[176]	_	_
22-23	3406-3414	response	event[176]	giv[176]	_	_
22-24	3415-3417	in	event[176]	giv[176]	_	_
22-25	3418-3419	a	event[176]|abstract[177]	giv[176]|giv[177]	_	_
22-26	3420-3429	naturally	event[176]|abstract[177]	giv[176]|giv[177]	_	_
22-27	3430-3433	and	event[176]|abstract[177]	giv[176]|giv[177]	_	_
22-28	3434-3446	asymptomatic	event[176]|abstract[177]	giv[176]|giv[177]	_	_
22-29	3447-3455	infected	event[176]|abstract[177]	giv[176]|giv[177]	_	_
22-30	3456-3461	model	event[176]|abstract[177]	giv[176]|giv[177]	_	_
22-31	3462-3463	.	_	_	_	_

#Text=The fact that an antigen generates a cellular response classified as type IV or late hypersensitivity implies that this antigen may be able to generate immune memory and trigger a response characterized by important cytokines , such as IFN-γ and TNF-α .
23-1	3464-3467	The	abstract[178]	new[178]	_	_
23-2	3468-3472	fact	abstract[178]	new[178]	_	_
23-3	3473-3477	that	abstract[178]	new[178]	_	_
23-4	3478-3480	an	abstract[178]|substance[179]	new[178]|giv[179]	coref	23-19[181_179]
23-5	3481-3488	antigen	abstract[178]|substance[179]	new[178]|giv[179]	_	_
23-6	3489-3498	generates	abstract[178]	new[178]	_	_
23-7	3499-3500	a	abstract[178]|event[180]	new[178]|giv[180]	coref	23-30[183_180]
23-8	3501-3509	cellular	abstract[178]|event[180]	new[178]|giv[180]	_	_
23-9	3510-3518	response	abstract[178]|event[180]	new[178]|giv[180]	_	_
23-10	3519-3529	classified	_	_	_	_
23-11	3530-3532	as	_	_	_	_
23-12	3533-3537	type	_	_	_	_
23-13	3538-3540	IV	_	_	_	_
23-14	3541-3543	or	_	_	_	_
23-15	3544-3548	late	_	_	_	_
23-16	3549-3565	hypersensitivity	_	_	_	_
23-17	3566-3573	implies	_	_	_	_
23-18	3574-3578	that	_	_	_	_
23-19	3579-3583	this	substance[181]	giv[181]	_	_
23-20	3584-3591	antigen	substance[181]	giv[181]	_	_
23-21	3592-3595	may	_	_	_	_
23-22	3596-3598	be	_	_	_	_
23-23	3599-3603	able	_	_	_	_
23-24	3604-3606	to	_	_	_	_
23-25	3607-3615	generate	_	_	_	_
23-26	3616-3622	immune	abstract[182]	giv[182]	_	_
23-27	3623-3629	memory	abstract[182]	giv[182]	_	_
23-28	3630-3633	and	_	_	_	_
23-29	3634-3641	trigger	_	_	_	_
23-30	3642-3643	a	event[183]	giv[183]	_	_
23-31	3644-3652	response	event[183]	giv[183]	_	_
23-32	3653-3666	characterized	_	_	_	_
23-33	3667-3669	by	_	_	_	_
23-34	3670-3679	important	abstract[184]	giv[184]	_	_
23-35	3680-3689	cytokines	abstract[184]	giv[184]	_	_
23-36	3690-3691	,	abstract[184]	giv[184]	_	_
23-37	3692-3696	such	abstract[184]	giv[184]	_	_
23-38	3697-3699	as	abstract[184]	giv[184]	_	_
23-39	3700-3705	IFN-γ	abstract[184]|abstract	giv[184]|giv	_	_
23-40	3706-3709	and	abstract[184]	giv[184]	_	_
23-41	3710-3715	TNF-α	abstract[184]|abstract	giv[184]|new	_	_
23-42	3716-3717	.	_	_	_	_

#Text=When we analyzed the epitope conservancy of these peptides among the proteome of other Leishmania species , it was observed that peptide PEP17 demonstrated to be the most conserved epitope among various viscerotropic and dermatotropic Leishmania species .
24-1	3718-3722	When	_	_	_	_
24-2	3723-3725	we	person	giv	_	_
24-3	3726-3734	analyzed	_	_	_	_
24-4	3735-3738	the	abstract[189]	new[189]	ana	24-18[0_189]
24-5	3739-3746	epitope	substance|abstract[189]	giv|new[189]	coref	24-27[197_0]
24-6	3747-3758	conservancy	abstract[189]	new[189]	_	_
24-7	3759-3761	of	abstract[189]	new[189]	_	_
24-8	3762-3767	these	abstract[189]|substance[190]	new[189]|giv[190]	coref	25-1[201_190]
24-9	3768-3776	peptides	abstract[189]|substance[190]	new[189]|giv[190]	_	_
24-10	3777-3782	among	_	_	_	_
24-11	3783-3786	the	abstract[191]	new[191]	_	_
24-12	3787-3795	proteome	abstract[191]	new[191]	_	_
24-13	3796-3798	of	abstract[191]	new[191]	_	_
24-14	3799-3804	other	abstract[191]|animal[193]	new[191]|new[193]	coref	24-35[200_193]
24-15	3805-3815	Leishmania	abstract[191]|animal|animal[193]	new[191]|giv|new[193]	_	_
24-16	3816-3823	species	abstract[191]|animal[193]	new[191]|new[193]	_	_
24-17	3824-3825	,	_	_	_	_
24-18	3826-3828	it	abstract	giv	coref	25-9[203_0]
24-19	3829-3832	was	_	_	_	_
24-20	3833-3841	observed	_	_	_	_
24-21	3842-3846	that	_	_	_	_
24-22	3847-3854	peptide	place	new	_	_
24-23	3855-3860	PEP17	substance	new	_	_
24-24	3861-3873	demonstrated	_	_	_	_
24-25	3874-3876	to	_	_	_	_
24-26	3877-3879	be	_	_	_	_
24-27	3880-3883	the	substance[197]	giv[197]	_	_
24-28	3884-3888	most	substance[197]	giv[197]	_	_
24-29	3889-3898	conserved	substance[197]	giv[197]	_	_
24-30	3899-3906	epitope	substance[197]	giv[197]	_	_
24-31	3907-3912	among	substance[197]	giv[197]	_	_
24-32	3913-3920	various	substance[197]|abstract[198]|abstract[199]	giv[197]|new[198]|new[199]	ana|ana	25-23[0_199]|25-23[0_199]
24-33	3921-3934	viscerotropic	substance[197]|abstract[198]|abstract[199]	giv[197]|new[198]|new[199]	_	_
24-34	3935-3938	and	substance[197]|abstract[199]	giv[197]|new[199]	_	_
24-35	3939-3952	dermatotropic	substance[197]|abstract[199]|animal[200]	giv[197]|new[199]|giv[200]	_	_
24-36	3953-3963	Leishmania	substance[197]|abstract[199]|animal[200]	giv[197]|new[199]|giv[200]	_	_
24-37	3964-3971	species	substance[197]|abstract[199]|animal[200]	giv[197]|new[199]|giv[200]	_	_
24-38	3972-3973	.	_	_	_	_

#Text=Immunogenic peptides that show a high degree of conservancy with other parasites may be related to a better protection when compared to those not conserved .
25-1	3974-3985	Immunogenic	substance[201]	giv[201]	coref	26-5[0_201]
25-2	3986-3994	peptides	substance[201]	giv[201]	_	_
25-3	3995-3999	that	_	_	_	_
25-4	4000-4004	show	_	_	_	_
25-5	4005-4006	a	abstract[202]	new[202]	_	_
25-6	4007-4011	high	abstract[202]	new[202]	_	_
25-7	4012-4018	degree	abstract[202]	new[202]	_	_
25-8	4019-4021	of	abstract[202]	new[202]	_	_
25-9	4022-4033	conservancy	abstract[202]|abstract[203]	new[202]|giv[203]	_	_
25-10	4034-4038	with	abstract[202]|abstract[203]	new[202]|giv[203]	_	_
25-11	4039-4044	other	abstract[202]|abstract[203]|animal[204]	new[202]|giv[203]|giv[204]	_	_
25-12	4045-4054	parasites	abstract[202]|abstract[203]|animal[204]	new[202]|giv[203]|giv[204]	_	_
25-13	4055-4058	may	_	_	_	_
25-14	4059-4061	be	_	_	_	_
25-15	4062-4069	related	_	_	_	_
25-16	4070-4072	to	_	_	_	_
25-17	4073-4074	a	abstract[205]	giv[205]	_	_
25-18	4075-4081	better	abstract[205]	giv[205]	_	_
25-19	4082-4092	protection	abstract[205]	giv[205]	_	_
25-20	4093-4097	when	_	_	_	_
25-21	4098-4106	compared	_	_	_	_
25-22	4107-4109	to	_	_	_	_
25-23	4110-4115	those	abstract	giv	_	_
25-24	4116-4119	not	_	_	_	_
25-25	4120-4129	conserved	_	_	_	_
25-26	4130-4131	.	_	_	_	_

#Text=In this way , peptides 17 , 30 , 33 , and 34 may be considered promising epitopes for the design of vaccines against VL .
26-1	4132-4134	In	_	_	_	_
26-2	4135-4139	this	abstract[207]	giv[207]	_	_
26-3	4140-4143	way	abstract[207]	giv[207]	_	_
26-4	4144-4145	,	_	_	_	_
26-5	4146-4154	peptides	substance	giv	_	_
26-6	4155-4157	17	quantity	new	_	_
26-7	4158-4159	,	_	_	_	_
26-8	4160-4162	30	time[210]	new[210]	_	_
26-9	4163-4164	,	time[210]	new[210]	_	_
26-10	4165-4167	33	time[210]|quantity	new[210]|new	_	_
26-11	4168-4169	,	_	_	_	_
26-12	4170-4173	and	_	_	_	_
26-13	4174-4176	34	quantity	new	_	_
26-14	4177-4180	may	_	_	_	_
26-15	4181-4183	be	_	_	_	_
26-16	4184-4194	considered	_	_	_	_
26-17	4195-4204	promising	_	_	_	_
26-18	4205-4213	epitopes	object[213]	giv[213]	_	_
26-19	4214-4217	for	object[213]	giv[213]	_	_
26-20	4218-4221	the	object[213]|abstract[214]	giv[213]|new[214]	_	_
26-21	4222-4228	design	object[213]|abstract[214]	giv[213]|new[214]	_	_
26-22	4229-4231	of	object[213]|abstract[214]	giv[213]|new[214]	_	_
26-23	4232-4240	vaccines	object[213]|abstract[214]|substance	giv[213]|new[214]|giv	_	_
26-24	4241-4248	against	object[213]|abstract[214]	giv[213]|new[214]	_	_
26-25	4249-4251	VL	object[213]|abstract[214]|abstract	giv[213]|new[214]|new	_	_
26-26	4252-4253	.	_	_	_	_
